This is a demo store. No orders will be fulfilled.
An adhesive hydrogel implant combining chemotherapy and tumor microenvironment remodeling for preventing postoperative recurrence and metastasis of breast cancer
Postoperative tumor microenvironments, such as cancer-associated adipocytes and angiogenesis, severely affect the recurrence and metastasis of residual tumor cells. Efficiently killing residual tumor cells and simultaneously blocking the function of cancer-associated adipocytes and inhibiting angiogenesis might be a promising strategy to prevent postoperative tumor recurrence and metastasis. Here, a bio-adhesive hydrogels grafting dopamine and 3-aminobenzeneboronic acid onto hyaluronic acid were facilely developed to load anticancer drug doxorubicin and metformin (DOX/Met@HDP) for postoperative in-situ treatment in breast cancer. After implantation into the tumor surgical cavity, DOX/Met@HDP persistently retains drugs at the tumor resection sites and releases drugs in a tumor acidic microenvironment-controlled manner. The released doxorubicin efficiently kills residual tumor cells, while the released metformin inhibits adipocyte function to abrogate the adipocyte-promoted proliferation and migration of tumor cells and suppresses tumor angiogenesis, resulting in the significant inhibition of postoperative tumor recurrence and metastasis. Our results demonstrate that DOX/Met@HDP is a potential implant for improving the prognosis of breast cancer patients undergoing surgery.